questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Effets physiologiques des médicaments
Facteurs immunologiques
Immunosuppresseurs
Immunosuppresseurs : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Immunosuppresseurs : Questions médicales les plus fréquentes",
"headline": "Immunosuppresseurs : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Immunosuppresseurs : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-27",
"dateModified": "2025-04-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Immunosuppresseurs"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Facteurs immunologiques",
"url": "https://questionsmedicales.fr/mesh/D007155",
"about": {
"@type": "MedicalCondition",
"name": "Facteurs immunologiques",
"code": {
"@type": "MedicalCode",
"code": "D007155",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.477"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du complément",
"alternateName": "Complement Inactivating Agents",
"url": "https://questionsmedicales.fr/mesh/D051056",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du complément",
"code": {
"@type": "MedicalCode",
"code": "D051056",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.477.656.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Antagonistes du récepteur B2 de la bradykinine",
"alternateName": "Bradykinin B2 Receptor Antagonists",
"url": "https://questionsmedicales.fr/mesh/D065094",
"about": {
"@type": "MedicalCondition",
"name": "Antagonistes du récepteur B2 de la bradykinine",
"code": {
"@type": "MedicalCode",
"code": "D065094",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.477.656.500.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des interleukines",
"alternateName": "Interleukin Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000088902",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des interleukines",
"code": {
"@type": "MedicalCode",
"code": "D000088902",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.477.656.563"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'interleukine-6",
"alternateName": "Interleukin-6 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000093242",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'interleukine-6",
"code": {
"@type": "MedicalCode",
"code": "D000093242",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.477.656.594"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Modulateurs des récepteurs de la sphingosine 1 phosphate",
"alternateName": "Sphingosine 1 Phosphate Receptor Modulators",
"url": "https://questionsmedicales.fr/mesh/D000081243",
"about": {
"@type": "MedicalCondition",
"name": "Modulateurs des récepteurs de la sphingosine 1 phosphate",
"code": {
"@type": "MedicalCode",
"code": "D000081243",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.477.656.875"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Immunosuppresseurs",
"alternateName": "Immunosuppressive Agents",
"code": {
"@type": "MedicalCode",
"code": "D007166",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Koichi Kamei",
"url": "https://questionsmedicales.fr/author/Koichi%20Kamei",
"affiliation": {
"@type": "Organization",
"name": "Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan. kamei-k@ncchd.go.jp."
}
},
{
"@type": "Person",
"name": "Masao Ogura",
"url": "https://questionsmedicales.fr/author/Masao%20Ogura",
"affiliation": {
"@type": "Organization",
"name": "Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Kensuke Shoji",
"url": "https://questionsmedicales.fr/author/Kensuke%20Shoji",
"affiliation": {
"@type": "Organization",
"name": "Division of Infectious Diseases, National Center for Child Health and Development, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Shuichi Ito",
"url": "https://questionsmedicales.fr/author/Shuichi%20Ito",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics, Yokohama City University Hospital, Kanagawa, Japan."
}
},
{
"@type": "Person",
"name": "Dorota Iwaszkiewicz-Grześ",
"url": "https://questionsmedicales.fr/author/Dorota%20Iwaszkiewicz-Grze%C5%9B",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Immunology, Faculty of Medicine, Medical University of Gdansk, ul. Dębinki 7, 80-210 Gdańsk, Poland."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant.",
"datePublished": "2022-10-17",
"url": "https://questionsmedicales.fr/article/36251860",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/13506129.2022.2131384"
}
},
{
"@type": "ScholarlyArticle",
"name": "Risk factors for cognitive dysfunction amongst patients with cardiovascular diseases.",
"datePublished": "2024-09-13",
"url": "https://questionsmedicales.fr/article/39346594",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fpubh.2024.1385089"
}
},
{
"@type": "ScholarlyArticle",
"name": "Reward network dysfunction is associated with cognitive impairment after stroke.",
"datePublished": "2023-05-31",
"url": "https://questionsmedicales.fr/article/37307650",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.nicl.2023.103446"
}
},
{
"@type": "ScholarlyArticle",
"name": "Predictors of cognitive dysfunction one-year post COVID-19.",
"datePublished": "2023-01-05",
"url": "https://questionsmedicales.fr/article/36603126",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1037/neu0000876"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cognitive Dysfunction Biomarkers in Patients With Rheumatoid Arthritis: A Systematic Review.",
"datePublished": "2022-12-07",
"url": "https://questionsmedicales.fr/article/36729842",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/RHU.0000000000001888"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Effets physiologiques des médicaments",
"item": "https://questionsmedicales.fr/mesh/D045505"
},
{
"@type": "ListItem",
"position": 5,
"name": "Facteurs immunologiques",
"item": "https://questionsmedicales.fr/mesh/D007155"
},
{
"@type": "ListItem",
"position": 6,
"name": "Immunosuppresseurs",
"item": "https://questionsmedicales.fr/mesh/D007166"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Immunosuppresseurs - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Immunosuppresseurs",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Immunosuppresseurs",
"description": "Comment diagnostiquer une nécessité d'immunosuppresseurs ?\nQuels tests sont utilisés pour évaluer l'immunité ?\nQuels signes indiquent un besoin d'immunosuppresseurs ?\nComment évaluer le risque de rejet d'organe ?\nQuels symptômes nécessitent un traitement immunosuppresseur ?",
"url": "https://questionsmedicales.fr/mesh/D007166?mesh_terms=Cognitive+Dysfunction&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Immunosuppresseurs",
"description": "Quels sont les effets secondaires des immunosuppresseurs ?\nComment reconnaître une infection due à l'immunosuppression ?\nQuels symptômes d'allergie peuvent survenir ?\nLes immunosuppresseurs causent-ils des troubles digestifs ?\nQuels signes indiquent une réaction indésirable ?",
"url": "https://questionsmedicales.fr/mesh/D007166?mesh_terms=Cognitive+Dysfunction&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Immunosuppresseurs",
"description": "Comment prévenir les infections sous immunosuppression ?\nQuelles précautions alimentaires prendre ?\nComment gérer le stress pendant le traitement ?\nQuels examens de suivi sont nécessaires ?\nComment éviter les interactions médicamenteuses ?",
"url": "https://questionsmedicales.fr/mesh/D007166?mesh_terms=Cognitive+Dysfunction&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Immunosuppresseurs",
"description": "Quels types d'immunosuppresseurs existent ?\nComment sont administrés les immunosuppresseurs ?\nQuelle est la durée du traitement immunosuppresseur ?\nComment ajuster la posologie des immunosuppresseurs ?\nQuels sont les traitements alternatifs aux immunosuppresseurs ?",
"url": "https://questionsmedicales.fr/mesh/D007166?mesh_terms=Cognitive+Dysfunction&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Immunosuppresseurs",
"description": "Quelles sont les complications possibles des immunosuppresseurs ?\nComment reconnaître une infection grave ?\nLes immunosuppresseurs augmentent-ils le risque de cancer ?\nQuels troubles métaboliques peuvent survenir ?\nComment gérer les complications liées aux immunosuppresseurs ?",
"url": "https://questionsmedicales.fr/mesh/D007166?mesh_terms=Cognitive+Dysfunction&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Immunosuppresseurs",
"description": "Quels facteurs augmentent le besoin d'immunosuppresseurs ?\nComment l'âge influence-t-il le traitement ?\nLe mode de vie affecte-t-il l'immunosuppression ?\nQuels médicaments augmentent le risque d'interactions ?\nLes antécédents familiaux influencent-ils le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D007166?mesh_terms=Cognitive+Dysfunction&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une nécessité d'immunosuppresseurs ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'évaluation clinique et des tests sanguins pour évaluer l'auto-immunité."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'immunité ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests comme le dosage des anticorps et des lymphocytes T sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent un besoin d'immunosuppresseurs ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des inflammations chroniques ou des éruptions cutanées peuvent indiquer ce besoin."
}
},
{
"@type": "Question",
"name": "Comment évaluer le risque de rejet d'organe ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par des tests de compatibilité et des marqueurs immunologiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes nécessitent un traitement immunosuppresseur ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue extrême ou des douleurs articulaires peuvent nécessiter un traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des immunosuppresseurs ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent infections, fatigue, et troubles gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une infection due à l'immunosuppression ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme fièvre, frissons ou douleurs inhabituelles peuvent indiquer une infection."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'allergie peuvent survenir ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, démangeaisons ou gonflements peuvent être des signes d'allergie."
}
},
{
"@type": "Question",
"name": "Les immunosuppresseurs causent-ils des troubles digestifs ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des nausées, vomissements ou diarrhées peuvent survenir avec certains immunosuppresseurs."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une réaction indésirable ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des douleurs abdominales ou des saignements peuvent signaler une réaction."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections sous immunosuppression ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est essentiel de se faire vacciner et d'éviter les contacts avec des personnes malades."
}
},
{
"@type": "Question",
"name": "Quelles précautions alimentaires prendre ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez les aliments crus et assurez-vous que les aliments sont bien cuits pour prévenir les infections."
}
},
{
"@type": "Question",
"name": "Comment gérer le stress pendant le traitement ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques de relaxation et un soutien psychologique peuvent aider à gérer le stress."
}
},
{
"@type": "Question",
"name": "Quels examens de suivi sont nécessaires ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers de la fonction rénale et des tests sanguins sont nécessaires pour le suivi."
}
},
{
"@type": "Question",
"name": "Comment éviter les interactions médicamenteuses ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Informez toujours votre médecin de tous les médicaments que vous prenez pour éviter les interactions."
}
},
{
"@type": "Question",
"name": "Quels types d'immunosuppresseurs existent ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux types incluent les corticostéroïdes, les inhibiteurs de calcineurine et les agents biologiques."
}
},
{
"@type": "Question",
"name": "Comment sont administrés les immunosuppresseurs ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être administrés par voie orale, intraveineuse ou sous-cutanée selon le médicament."
}
},
{
"@type": "Question",
"name": "Quelle est la durée du traitement immunosuppresseur ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée varie selon la maladie, allant de quelques mois à plusieurs années."
}
},
{
"@type": "Question",
"name": "Comment ajuster la posologie des immunosuppresseurs ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La posologie est ajustée en fonction des résultats des tests sanguins et de la réponse clinique."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements alternatifs aux immunosuppresseurs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements alternatifs incluent des thérapies biologiques et des médicaments anti-inflammatoires."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des immunosuppresseurs ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections graves, des cancers et des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une infection grave ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme une forte fièvre, des frissons ou une confusion peuvent indiquer une infection grave."
}
},
{
"@type": "Question",
"name": "Les immunosuppresseurs augmentent-ils le risque de cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'utilisation prolongée d'immunosuppresseurs peut augmenter le risque de certains cancers."
}
},
{
"@type": "Question",
"name": "Quels troubles métaboliques peuvent survenir ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles comme le diabète ou l'hypertension peuvent survenir avec certains immunosuppresseurs."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées aux immunosuppresseurs ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi régulier, des ajustements de traitement et une surveillance des symptômes."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le besoin d'immunosuppresseurs ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents de maladies auto-immunes ou de transplantation augmentent ce besoin."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il le traitement ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées peuvent avoir un risque accru d'effets secondaires et nécessiter des ajustements."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il l'immunosuppression ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut réduire les risques d'infections et améliorer la réponse au traitement."
}
},
{
"@type": "Question",
"name": "Quels médicaments augmentent le risque d'interactions ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains antibiotiques et antifongiques peuvent interagir avec les immunosuppresseurs."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le traitement ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies auto-immunes peuvent augmenter le risque de développer des maladies similaires."
}
}
]
}
]
}
Cognitive dysfunction is part of the broad spectrum of clinical manifestations in older untreated hereditary transthyretin amyloidosis patients with peripheral polyneuropathy....
The objective of this study is to systematically explore cognitive dysfunction in ATTRV30M amyloidosis patients whose disease course was modified by liver transplant (LT)....
A series of 269 carriers of TTRVal30Met mutation treated with LT underwent a neuropsychological assessment. Clinical charts were reviewed to identify focal neurological episodes (FNEs), cognitive comp...
Cognitive dysfunction was identified in 35 patients (13%)-14 (5%) had mild and 21 (8%) had moderate dysfunction. In comparison to normal cognition, both mild and moderate cognitive dysfunction patient...
Consistent with the natural history of the disease, older age and higher severity of the disease are significantly associated and potentially predictors of cognitive dysfunction in ATTRV30M patients t...
The impact of cardiovascular diseases on cognition raises important research questions. The study aimed to investigate the relationship between demographic data, cardiovascular diseases, kidney diseas...
A cross-sectional study of patients with cardiovascular diseases was performed. The Montreal Cognitive Assessment (MoCA) was applied for cognitive evaluation. Based on MoCA three groups were defined: ...
Of 628 patients, 55.2% had mild CD, and the mean age was 67.95 (SD 9.53) years. Cα and Mω were 0.7, indicating good internal consistency. We found a moderate positive correlation between depression an...
Mild CD was the most common in patients with cardiovascular diseases. Older age, lower education, being a non-smoker, and renal dysfunction were risk factors for both mild and advanced CD. Female gend...
Stroke survivors not only suffer from severe motor, speech and neurocognitive deficits, but in many cases also from a "lack of pleasure" and a reduced motivational level. Especially apathy and anhedon...
(a) To characterize the frequency of objective cognitive deficits and self-perceived cognitive difficulties and (b) to explore demographic and clinical predictors of cognitive dysfunction and cognitiv...
One hundred and ten adults diagnosed with COVID-19 between March and November 2020, aged ≤ 74 years underwent a brief neuropsychological evaluation 12 months after infection, which included: Brief Vis...
Twenty participants (18.2%) had cognitive dysfunction and 36 (33.3%) had cognitive complaints. Cognitive dysfunction was related to lower education, preinfection history of headache/migraine, and acut...
A subset of individuals develops cognitive difficulties in the context of post-COVID syndrome. Results may support the protective effect of education, a known proxy of cognitive reserve. COVID-19 infe...
During the last years, a growing number of studies have investigated the link between cognitive dysfunction and rheumatoid arthritis (RA), highlighting the potential pathogenic role of several clinica...
We performed a systematic review using PRISMA (Preferred Reported Items for Systematic Reviews and Meta-analysis) protocol. A systematic search was conducted in the PubMed/MEDLINE, EMBASE, LILACS, Sco...
Five original studies were included, which provided data from 428 participants. Among plasma proteins, SHH was increased and TTR was reduced in patients with mild cognitive impairment; anti-myelin bas...
Despite the relative scarcity of studies on this subject and the heterogeneity of results, we identified possible biomarkers for cognitive deficits in the RA population. Further longitudinal studies a...
Toll-like receptors (TLRs) are pattern recognition receptors (PRRs) with a well-documented role in the innate and adaptive immune responses. Interestingly, TLR activation has also been linked to sever...
The origin of pre-existing cognitive impairment in stroke patients remains controversial, with a vascular or a degenerative hypothesis....
To determine whether endothelial dysfunction is associated with pre-existing cognitive problems, lesion load and biological anomalies in stroke patients....
Patients originated from the prospective STROKDEM study. The baseline cognitive state, assessed using the IQ-CODE, and risk factors for stroke were recorded at inclusion. Patients with an IQ-CODE scor...
A total of 86 patients were included (52 males; mean age 63.5 ± 11.5 years). Patients with abnormal RHI have hypertension or antihypertensive treatment more often. The baseline IQ-CODE was abnormal in...
A vascular mechanism may be responsible for cognitive problems pre-existing stroke. The measurement of endothelial dysfunction after stroke could become an important element of follow-up, providing an...
There is increasing recognition of the prevalence and impact of cognitive dysfunction (CD) in heart failure (HF) patients. This contemporary review appraises the evidence for epidemiological associati...
CD disproportionately affects heart failure patients, even accounting for known comorbid risk factors, and this may extend to subclinical left ventricular dysfunction. Neuroimaging studies now provide...
Cognitive dysfunction is increasingly recognized as a complication and comorbidity of diabetes, supported by evidence of abnormal brain structure and function. Although few mechanistic metabolic studi...
There is limited data on cognition in patients undergoing peritoneal dialysis (PD). We assessed prevalence and associated risk factors of neurocognitive impairment (NCI) in PD patients....
A cross-sectional cohort study of 149 PD patients at a single centre between 2016 and 2020 who underwent neurocognitive screening at defined intervals by Addenbrooke's Cognitive Examination - Revised ...
Patients on PD performed poorly in ACE-R screening compared to population norms, with discrepancy in all cognitive domains. In patients without CVD, attention and language domains were comparable to n...
Patients on PD have higher prevalence of NCI than the general population, primarily with impairments in memory, fluency and visuospatial reasoning. CVD confers poorer performance in attention and lang...